Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases

References

• ColemanREMetastatic bone disease: Clinical features, pathophysiology and treatment strategiesCancer Treat Rev200127316517611417967
   PubMed Web of Science ®Google Scholar
• SmithHSPainful osseous metastasesPain Physician2011144E37340321785487
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJBellROral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerPain2004111330631215363874
   PubMed Web of Science ®Google Scholar
• WeinfurtKPLiYCastelLDThe significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancerAnn Oncol200516457958415734776
   PubMed Web of Science ®Google Scholar
• AaproMAbrahamssonPABodyJJGuidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panelAnn Oncol200819342043217906299
   PubMed Web of Science ®Google Scholar
• ColemanREGuiseTALiptonAAdvancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge ConferenceClin Cancer Res200814206387639518927277
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDTchekmedyianNSLong-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trialCancer2004100122613262115197804
   PubMed Web of Science ®Google Scholar
• ZOMETA® (zoledronic acid injection) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2012
   Google Scholar
• PageauSCDenosumabMAbs20091321021520065634
   PubMed Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyJ Clin Oncol201028355132513921060033
   PubMed Web of Science ®Google Scholar
• XGEVA®(denosumab injection) [package insert]Thousand Oaks, CAAmgen, Inc2013
   Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• LiptonASienaSRaderMComparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials [Abstract]Ann Oncol201021Suppl 8viii380
   Google Scholar
• CavaliereCMChungKCA cost-utility analysis of nonsurgical management, total wrist arthroplasty, and total wrist arthrodesis in rheumatoid arthritisJ Hand Surg Am201035337939120193858
   PubMed Web of Science ®Google Scholar
• ChancellorJAballéaSLawrenceAPreferences of patients with diabetes mellitus for inhaled versus injectable insulin regimensPharmacoeconomics200826321723418282016
   PubMed Web of Science ®Google Scholar
• HuangESShookMJinLChinMHMeltzerDOThe impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetesDiabetes Care200629225926416443870
   PubMed Web of Science ®Google Scholar
• OsborneRHDe Abreu LourençoRDaltonAQuality of life related to oral versus subcutaneous iron chelation: a time trade-off studyValue Health200710645145617970927
   PubMed Web of Science ®Google Scholar
• PolsterMZanuttoEMcDonaldSConnerCHammerMA comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetesJ Med Econ201013465566121034377
   PubMedGoogle Scholar
• BoyeKSMatzaLSWalterKNVan BruntKPalsgroveACTynanAUtilities and disutilities for attributes of injectable treatments for type 2 diabetesEur J Health Econ201112321923020224930
   PubMed Web of Science ®Google Scholar
• OsborneRHDaltonAHertelJSchroverRSmithDKHealth-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off studyHealth Qual Life Outcomes2012103522472127
   PubMed Web of Science ®Google Scholar
• TeuffelOChengSEthierMCHealth-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patientsSupport Care Cancer201220112755276422350594
   PubMed Web of Science ®Google Scholar
• FeenyDTownsendMFurlongWHealth-related quality-of-life assessment of prenatal diagnosis: chorionic villi sampling and amniocentesisGenet Test200261394612180075
   PubMedGoogle Scholar
• GageBFCardinalliABAlbersGWOwensDKCost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillationJAMA199527423183918457500532
   PubMed Web of Science ®Google Scholar
• JewellELSmrtkaMBroadwaterGUtility scores and treatment preferences for clinical early-stage cervical cancerValue Health201114458258621669383
   PubMed Web of Science ®Google Scholar
• WuJMFultonRGAmundsenCLKnightSKKuppermannMPatient preferences for different severities of and treatments for overactive bladderFemale Pelvic Med Reconstr Surg201117418418922453849
   PubMed Web of Science ®Google Scholar
• ChapelHMSpickettGPEricsonDThe comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapyJ Clin Immunol20002029410010821460
   PubMed Web of Science ®Google Scholar
• ChiltonFCollettRATreatment choices, preferences and decision-making by patients with rheumatoid arthritisMusculoskeletal Care20086111417726671
   PubMedGoogle Scholar
• RobinsonAMMcLeanKAGreavesMChannerKSSubcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? A randomized cross-over studyPostgrad Med J1993698081151168506190
   PubMed Web of Science ®Google Scholar
• MatzaLSVan BruntKChungKCHealth state utilities for skeletal-related events associated with bone metastasesPaper presented at: ASCO 2011June 3–7, 2011Chicago, IL, USA
   Google Scholar
• BodyJJFaconTColemanREA study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerClin Cancer Res20061241221122816489077
   PubMed Web of Science ®Google Scholar
• LiptonAZhengMSeamanJZoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinomaCancer200398596296912942563
   PubMed Web of Science ®Google Scholar
• McKeageKPloskerGLZoledronic acid: a pharmacoeconomic review of its use in the management of bone metastasesPharmacoeconomics200826325126818282018
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRZolendronic Acid Prostate Cancer Study GroupA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMed Web of Science ®Google Scholar
• Barrett-LeePBloomfieldDDoughertyLAn audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital settingCurr Med Res Opin20072371575158217559749
   PubMed Web of Science ®Google Scholar
• RichhariyaAQianYZhaoYChungKTime associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasisCancer Manag Res20124556022427731
   PubMedGoogle Scholar
• AREDIA®(pamidronate disodium injection) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2011
   Google Scholar
• ContePGuarneriVSafety of intravenous and oral bisphosphonates and compliance with dosing regimensOncologist20049Suppl 4283715459427
   PubMed Web of Science ®Google Scholar
• AbdullaAKapoorAEmerging novel therapies in the treatment of castrate-resistant prostate cancerCan Urol Assoc J20115212013321470540
   PubMed Web of Science ®Google Scholar
• HassanMSAnsariJSpoonerDHussainSAChemotherapy for breast cancer (Review)Oncol Rep20102451121113120878101
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRTAX 327 InvestigatorsDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• BrazierJValuing health states for use in cost-effectiveness analysisPharmacoeconomics200826976977918767897
   PubMed Web of Science ®Google Scholar
• NICEGuide to the Methods of Technology AppraisalLondonNational Institute for Health and Clinical Excellence2008 Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/GuideToMethodsTechnologyAppraisal2008.jsp?domedia=1&mid=B52851A3-19B9-E0B5-D48284D172BD8459Accessed May 10, 2013
   Google Scholar
• Pharmaceutical Benefits Advisory Committee (PBAC)Guidelines for Preparing Submissions to PBAC, Version 4.3CanberraPharmaceutical Benefts Advisory Committee2008
   Google Scholar
• BrazierJRatcliffeJTsuchiyaASalomonJMeasuring and Valuing Health Benefits for Economic EvaluationNew York, NYOxford University Press2007
   Google Scholar
• DolanPGudexCKindPWilliamsAThe time trade-off method: results from a general population studyHealth Econ1996521411548733106
   PubMed Web of Science ®Google Scholar
• ColemanREClinical features of metastatic bone disease and risk of skeletal morbidityClin Cancer Res20061220 Pt 26243s6249s17062708
   PubMed Web of Science ®Google Scholar
• RowenDBrazierJHealth utility measurementGliedSSmithPCThe Oxford Handbook of Health EconomicsNew York, NYOxford University Press2011788813
   Google Scholar
• MatzaLSBoyeKSYurginNUtilities and disutilities for type 2 diabetes treatment-related attributesQual Life Res20071671251126517638121
   PubMed Web of Science ®Google Scholar
• LaupacisABourneRRorabeckCThe effect of elective total hip replacement on health-related quality of lifeJ Bone Joint Surg Am19937511161916268245054
   PubMed Web of Science ®Google Scholar
• ChouinardGAlbrightPSEconomic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidolJ Clin Psychopharmacol19971742983079241010
   PubMed Web of Science ®Google Scholar
• DalyEGrayABarlowDMcPhersonKRocheMVesseyMMeasuring the impact of menopausal symptoms on quality of lifeBMJ199330769088368408401125
   PubMed Web of Science ®Google Scholar
• HorsmanJFurlongWFeenyDTorranceGThe Health Utilities Index (HUI): concepts, measurement properties and applicationsHealth Qual Life Outcomes200315414613568
   PubMedGoogle Scholar
• GarauMShahKKMasonARWangQTowseADrummondMFUsing QALYs in cancer: a review of the methodological limitationsPharmacoeconomics201129867368521599035
   PubMed Web of Science ®Google Scholar